U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H35ClNO3S.Na
Molecular Weight 608.165
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MONTELUKAST SODIUM

SMILES

[Na+].CC(C)(O)C1=C(CC[C@@H](SCC2(CC([O-])=O)CC2)C3=CC(\C=C\C4=NC5=CC(Cl)=CC=C5C=C4)=CC=C3)C=CC=C1

InChI

InChIKey=LBFBRXGCXUHRJY-HKHDRNBDSA-M
InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C35H35ClNO3S
Molecular Weight 585.175
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67093875

Montelukast (SINGULAIR®) is a selective and orally active leukotriene D4 (LTD4) receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. It is indicated for the prophylaxis and chronic treatment of asthma, for prevention of exercise-induced bronchoconstriction, and for the relief of symptoms of seasonal allergic rhinitis. LTD4 is a product of arachidonic acid metabolism and is released from various cells, including mast cells and eosinophils. This eicosanoid binds to CysLT1 receptor found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). Cysteinyl leukotriene receptors (CysLTs) have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both earlyand late-phase reactions and are associated with symptoms of allergic rhinitis. Montelukast (SINGULAIR®) binds with high affinity and selectivity to the CysLT1 (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or beta-adrenergic receptor). It inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.

CNS Activity

Curator's Comment: Neuropsychiatric events have been reported with SINGULAIR®.

Originator

Curator's Comment: # Merck & Co., Inc.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SINGULAIR

Approved Use

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: •Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). •Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). •Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.3 Allergic Rhinitis Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older.

Launch Date

1998
Preventing
SINGULAIR

Approved Use

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: •Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). •Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). •Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.3 Allergic Rhinitis Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older.

Launch Date

1998
Primary
SINGULAIR

Approved Use

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: •Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). •Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). •Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.3 Allergic Rhinitis Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older.

Launch Date

1998
Primary
SINGULAIR

Approved Use

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: •Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). •Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). •Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.3 Allergic Rhinitis Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older.

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
541.5 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
602.8 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.8 ng/mL
1 mg single, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
18.5 ng/mL
1 mg single, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
224 ng/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
23.4 ng/mL
1 mg 1 times / day multiple, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
54.3 ng/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
184 ng/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
225 ng/mL
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
233 ng/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
242 ng/mL
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
44.3 ng/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.1 ng/mL
0.3 mg single, respiratory
dose: 0.3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.24 ng/mL
0.3 mg single, respiratory
dose: 0.3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
60 ng/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
64.8 ng/mL
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
76 ng/mL
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3540 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3978 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
132 ng*h/mL
1 mg single, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1500 ng*h/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
155 ng*h/mL
1 mg single, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1576 ng*h/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1600 ng*h/mL
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1850 ng*h/mL
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1880 ng*h/mL
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
214 ng*h/mL
1 mg 1 times / day multiple, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
357 ng*h/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
403 ng*h/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
491 ng*h/mL
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
526 ng*h/mL
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
576 ng*h/mL
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.6 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MONTELUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.7 h
1 mg single, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.7 h
10 mg single, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
8.2 h
1 mg 1 times / day multiple, respiratory
dose: 1 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
6.9 h
3 mg single, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: single
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
7.4 h
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
7.7 h
10 mg 1 times / day multiple, respiratory
dose: 10 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
7.6 h
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
8.1 h
3 mg 1 times / day multiple, respiratory
dose: 3 mg
route of administration: respiratory
experiment type: multiple
co-administered:
MONTELUKAST plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
healthy, 21-40 years
n = 18
Health Status: healthy
Age Group: 21-40 years
Sex: M
Population Size: 18
Sources:
7 mg single, intravenous
Dose: 7 mg
Route: intravenous
Route: single
Dose: 7 mg
Sources:
unhealthy, 29.8 years (range: 15.0–56.0 years)
n = 50
Health Status: unhealthy
Condition: asthma
Age Group: 29.8 years (range: 15.0–56.0 years)
Sex: M+F
Population Size: 50
Sources:
Other AEs: Headache...
Other AEs:
Headache (2%)
Sources:
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Condition: asthma
Age Group: 3 years
Population Size: 1
Sources:
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, 34 years (range: 18-54 years)
n = 28
Health Status: unhealthy
Condition: chronic asthma
Age Group: 34 years (range: 18-54 years)
Sex: M+F
Population Size: 28
Sources:
Other AEs: Bilirubin total increased, Alanine aminotransferase increase...
Other AEs:
Bilirubin total increased (mild, 1 patient)
Alanine aminotransferase increase (mild, 1 patient)
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Jaundice, Pruritus...
AEs leading to
discontinuation/dose reduction:
Jaundice (1 patient)
Pruritus (severe, 1 patient)
Nausea (1 patient)
Sources:
1000 ug single, respiratory
Dose: 1000 ug
Route: respiratory
Route: single
Dose: 1000 ug
Sources:
unhealthy, 39.1 years (range: 16.0–63.0 years)
n = 36
Health Status: unhealthy
Condition: chronic asthma
Age Group: 39.1 years (range: 16.0–63.0 years)
Sex: M+F
Population Size: 36
Sources:
135 mg single, oral
Overdose
Dose: 135 mg
Route: oral
Route: single
Dose: 135 mg
Sources:
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: asthma
Age Group: 5 years
Population Size: 1
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, >15 years
Other AEs: Psychiatric disorder NOS...
AEs

AEs

AESignificanceDosePopulation
Headache 2%
7 mg single, intravenous
Dose: 7 mg
Route: intravenous
Route: single
Dose: 7 mg
Sources:
unhealthy, 29.8 years (range: 15.0–56.0 years)
n = 50
Health Status: unhealthy
Condition: asthma
Age Group: 29.8 years (range: 15.0–56.0 years)
Sex: M+F
Population Size: 50
Sources:
Alanine aminotransferase increase mild, 1 patient
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, 34 years (range: 18-54 years)
n = 28
Health Status: unhealthy
Condition: chronic asthma
Age Group: 34 years (range: 18-54 years)
Sex: M+F
Population Size: 28
Sources:
Bilirubin total increased mild, 1 patient
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, 34 years (range: 18-54 years)
n = 28
Health Status: unhealthy
Condition: chronic asthma
Age Group: 34 years (range: 18-54 years)
Sex: M+F
Population Size: 28
Sources:
Jaundice 1 patient
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Pruritus severe, 1 patient
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Psychiatric disorder NOS serious
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, >15 years
PubMed

PubMed

TitleDatePubMed
Pharmacology of leukotriene receptor antagonists.
1998 Jun
Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway.
1998 May
Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma.
1999 Dec
Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group.
1999 Dec
Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers.
1999 Sep
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000 Aug
A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization.
2000 Dec 29
Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers.
2000 Feb
Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents.
2000 Jun
Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma.
2000 Sep
The protective effects of leukotriene modifiers in aspirin-induced asthma.
2000 Sep 15
LTRA inhibition of exercise-induced bronchoconstriction.
2000 Sep 15
Dose selection and dosing interval determination for LTRA use in asthma.
2000 Sep 15
Characterization of the human cysteinyl leukotriene 2 receptor.
2000 Sep 29
Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years.
2001 Jan
Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older.
2001 Jun
Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
2001 Oct 19
Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma.
2002 Apr 15
Effects of montelukast and beclomethasone on airway function and asthma control.
2002 Dec
Montelukast-associated Churg-Strauss syndrome.
2003 Sep
Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1.
2004 Apr
Montelukast-induced hepatitis.
2004 Apr 6
Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism.
2004 Feb
Role of leukotriene inhibitors in the postoperative management of nasal polyps.
2005
Examination of 209 drugs for inhibition of cytochrome P450 2C8.
2005 Jan
Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.
2006 Feb 15
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
2006 Jul
Effects of leukotriene receptor antagonists on monocyte chemotaxis, p38 and cytoplasmic calcium.
2006 Jun
Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.
2007 Dec 13
Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial.
2007 Oct
CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients.
2007 Sep
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
2007 Sep
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
2008
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
2008 Feb
Cysteinyl leukotrienes mediate the enhancing effects of indomethacin and aspirin on eosinophil production in murine bone marrow cultures.
2008 Feb
Leukotriene D4 increases the excitability of capsaicin-sensitive nasal sensory nerves to electrical and chemical stimuli.
2008 Jul
Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity.
2008 May
Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
2008 Nov 19
Cysteinyl leucotriene receptor type 1 mediates contraction in human and guinea-pig oesophagus.
2008 Oct
Montelukast-associated Churg-Strauss vasculitis: another associated report.
2009 Apr
Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
2009 Apr 23
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
2009 Dec
Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.
2009 Jun
Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea.
2009 May
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
2011 Dec 8
Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients.
2011 Oct
Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking.
2012 Dec
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

SINGULAIR® should be taken once daily in the evening. The following dose is recommended for adults and adolescents 15 years of age and older: one 10-mg tablet.
Route of Administration: Oral
In Vitro Use Guide
Montelukast is a potent and selective inhibitor of [3H]leukotriene D4 specific binding in guinea pig lung (Ki 0.18 +/- 0.03 nM), sheep lung (Ki 4 nM), and dimethylsulfoxide-differentiated U937 cell plasma membrane preparations (Ki 0.52 +/- 0.23 nM), but it was essentially inactive versus [3H]leukotriene C4 specific binding in dimethylsulfoxide-differentiated U937 cell membranes (IC50 10 microM) and [3H]leukotriene B4 specific binding in THP-1 cell membranes (IC50 40 microM). Montelukast also inhibited specific binding of [3H]leukotriene D4 to guinea pig lung in the presence of human serum albumin, human plasma, and squirrel monkey plasma with Ki values of 0.21 +/- 0.08, 0.19 +/- 0.02, and 0.26 +/- 0.02 nM, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:53:53 GMT 2023
Edited
by admin
on Fri Dec 15 15:53:53 GMT 2023
Record UNII
U1O3J18SFL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MONTELUKAST SODIUM
JAN   MART.   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
CYCLOPROPANEACETIC ACID, 1-(((1-(3-(2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)THIO)METHYL)-, SODIUM SALT, (R-(E))-
Common Name English
MONTELUKAST SODIUM [USP-RS]
Common Name English
MONTELUKAST SODIUM [VANDF]
Common Name English
SINGULAIR
Brand Name English
MONTELUKAST SODIUM [USAN]
Common Name English
MONTELUKAST MONOSODIUM SALT [MI]
Common Name English
MONTELUKAST SODIUM [EP MONOGRAPH]
Common Name English
MONTELUKAST SODIUM [ORANGE BOOK]
Common Name English
MONTELUKAST MONOSODIUM SALT
MI  
Common Name English
NSC-759107
Code English
MONTELUKAST (AS SODIUM)
Common Name English
MONTELUKAST SODIUM [MART.]
Common Name English
SODIUM 1-((((R)-M-((E)-2-(7-CHLORO-2-QUINOLYL)VINYL)-.ALPHA.-(O-(1-HYDROXY-1-METHYLETHYL)PHENETHYL)BENZYL)THIO)METHYL)CYCLOPROPANEACETATE
Common Name English
Montelukast sodium [WHO-DD]
Common Name English
MK-476
Code English
MONTELUKAST SODIUM [JAN]
Common Name English
MONTELUKAST SODIUM [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29712
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
Code System Code Type Description
EVMPD
SUB03324MIG
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
PUBCHEM
23663996
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
DRUG BANK
DBSALT001043
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
RXCUI
115713
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL787
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
CAS
151767-02-1
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
USAN
GG-39
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
NCI_THESAURUS
C47625
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
DAILYMED
U1O3J18SFL
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
SMS_ID
100000091459
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
NSC
759107
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
CHEBI
6993
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
FDA UNII
U1O3J18SFL
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID8046450
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
RS_ITEM_NUM
1446859
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY
MERCK INDEX
m7616
Created by admin on Fri Dec 15 15:53:53 GMT 2023 , Edited by admin on Fri Dec 15 15:53:53 GMT 2023
PRIMARY Merck Index
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
sum of impurities D and E: maximum 0.15 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
Michael Adducts 1 and 2- 0.15 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
Michael Adducts 1 and 2- 0.15 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities D and E: maximum 0.15 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY